The research by Kochi-based doctor Padmanabha D Shenoy says data is there to suggest Cyclophosphamide (CYC) and Mycophenolate Mofetil (MMF) are effective in management of scleroderma interstitial lung disease (SSc-ILD).
The study, published in the latest issue of international medical journal 'Arthritis Research and Therapy' is expected to give relief to lakhs of people who suffer from Scleroderma-- a systemic autoimmune disease characterised mainly by skin manifestations and involvement of various visceral organs, especially the lungs, Shenoy said here.
"Approximately 80 per cent of patients have evidence of pulmonary fibrosis at post-mortem examination or on high esolution computed tomography, although clinically evident disease is present only in approximately 40 per cent of patients," it said.
"CYC is a cytotoxic immunosuppressive agent that suppresses lymphokine production and modulates lymphocyte function by alkylating various cellular constituents and depressing the inflammatory response via normalisation of neutrophilia and healing of vascular endothelial cells.
"CYC is the only agent shown to at least stabilise lung function in a randomized, controlled trial," it said.
According to the research, Mycophenolic acid has emerged recently as a promising therapy for SSc.
"Evidence supporting its use derives from small, uncontrolled, single-arm studies, suggesting that mycophenolate is a safe therapeutic modality associated with functional stabilisation of SSc-ILD," the paper said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
